BIOLASE Inc (NASDAQ:BIOL) Given Consensus Recommendation of “Buy” by Analysts

Shares of BIOLASE Inc (NASDAQ:BIOL) have been given a consensus recommendation of “Buy” by the six analysts that are presently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $2.50.

Several equities analysts recently commented on BIOL shares. Ascendiant Capital Markets set a $3.00 target price on BIOLASE and gave the stock a “buy” rating in a research report on Monday, August 12th. ValuEngine cut BIOLASE from a “buy” rating to a “hold” rating in a research report on Thursday, September 26th. Benchmark started coverage on BIOLASE in a research report on Wednesday, June 19th. They set a “speculative buy” rating and a $2.00 target price for the company. Finally, Zacks Investment Research cut BIOLASE from a “buy” rating to a “hold” rating in a research report on Wednesday.

A hedge fund recently raised its stake in BIOLASE stock. BlackRock Inc. raised its holdings in shares of BIOLASE Inc (NASDAQ:BIOL) by 3.4% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 298,875 shares of the medical technology company’s stock after buying an additional 9,698 shares during the quarter. BlackRock Inc. owned about 1.40% of BIOLASE worth $440,000 as of its most recent filing with the Securities & Exchange Commission. 37.80% of the stock is owned by institutional investors.

Shares of NASDAQ BIOL traded up $0.01 during mid-day trading on Thursday, hitting $0.80. The company had a trading volume of 2,569 shares, compared to its average volume of 61,243. The company has a market capitalization of $17.53 million, a price-to-earnings ratio of -0.96 and a beta of 2.25. BIOLASE has a 1 year low of $0.76 and a 1 year high of $2.87. The company has a current ratio of 2.04, a quick ratio of 1.11 and a debt-to-equity ratio of 3.51. The stock’s 50-day moving average price is $1.01 and its 200-day moving average price is $1.62.

BIOLASE (NASDAQ:BIOL) last announced its quarterly earnings results on Thursday, August 8th. The medical technology company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.03. BIOLASE had a negative return on equity of 159.26% and a negative net margin of 47.46%. The company had revenue of $8.65 million during the quarter, compared to analysts’ expectations of $12.76 million. As a group, equities research analysts forecast that BIOLASE will post -0.59 earnings per share for the current year.

About BIOLASE

BIOLASE, Inc, a medical device company, develops, manufactures, markets, and sells laser systems in dentistry and medicine for patients and health care professionals in the worldwide. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; and diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening.

See Also: Stocks Increasing Dividends